In a report released today, Steve Baxter from Wells Fargo maintained a Buy rating on Humana (HUM – Research Report), with a price target of $350.00. The company’s shares closed last Friday at $313.11.
According to TipRanks, Baxter is an analyst with an average return of -0.7% and a 44.44% success rate. Baxter covers the Healthcare sector, focusing on stocks such as Humana, Elevance Health, and Molina Healthcare.
In addition to Wells Fargo, Humana also received a Buy from Goldman Sachs’s Nathan Rich in a report issued on April 3. However, today, Barclays maintained a Hold rating on Humana (NYSE: HUM).
Based on Humana’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $26.46 billion and a GAAP net loss of $541 million. In comparison, last year the company earned a revenue of $22.44 billion and had a GAAP net loss of $15 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Humana (HUM) Company Description:
Humana Inc. is a leading health insurance service provider in the United States. The company, through its Retail division, provides medicare benefits and state-based medicaid contracts, which are marketed on a retail basis to individuals. The Group and Specialty business offers employer group commercial fully-insured medical products and specialty health insurance benefits. Humana offers pharmacy solutions, provider services, home-based services, and clinical programs to the company’s health plan members as well as to third parties through the Healthcare Services segment.
